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Abstract
Background There is lack of uniformity in the utilization
of peritoneal cytology in gastric cancer management. The
identification of intraperitoneal free cancer cells (IFCCs) is
believed to confer poor prognosis. However, while some of
these patients are palliated, others may undergo more
aggressive therapies. In this review, we aimed to identify
and synthesize findings on the use of peritoneal cytology in
predicting peritoneal recurrence and overall survival in
curative gastric cancer patients.
Methods Electronic literature searches were conducted
using Medline, EMBASE, and the Cochrane Central Reg-
ister of Controlled Trials from January 1, 1998 to
December 31, 2009. We determined the accuracy, sensi-
tivity, and specificity of peritoneal cytology in predicting
peritoneal recurrence based on four techniques—conven-
tional cytology, immunoassay, immunohistochemistry, and
reverse transcriptase-polymerase chain reaction. Recur-
rence rates and overall survival rates for curative patients
were determined, based on positivity or negativity for
IFCCs.
Results Twenty-eight articles were included. All four
techniques showed wide variations in accuracy, sensitivity,
and specificity in predicting peritoneal recurrence. Recur-
rence rates for patients positive for IFCCs ranged from 11.1
to 100%, while those negative for IFCCs had recurrence
rates of 0–51%. Overall survival was significantly reduced
for patients with positive IFCCs. Short follow-up periods
and possible duplication of results may limit result
interpretation.
Conclusion The presence of IFCCs appears to increase
the risk of peritoneal recurrence and is associated with
worse overall survival in gastric cancer patients. Further
incorporation of peritoneal cytology in clinical decision-
making in gastric cancer depends on the development
of a consistently accurate and rapid IFCC detection
method.
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Introduction
The assessment of peritoneal lavage or ascitic fluid in
gastric cancer patients serves to identify patients who,
despite no evidence of gross peritoneal disease, have
intraperitoneal free cancer cells (IFCCs). The identifica-
tion of IFCCs in gastric cancer patients has been used to
predict the risk of peritoneal cancer recurrence and
predict overall survival [1–3]. Patients with IFCCs have
a poorer prognosis compared to those with no IFCCs [4,
5].With peritoneal dissemination being the most common
pattern of metastasis and recurrence in gastric carcinoma,
the identification of IFCCs seems prudent [1]. To this
end, the most recent TNM classification has included
IFCC detection as part of the staging process, denoting
M1 disease [6]. Traditionally, these patients were con-
sidered only for palliation [7]; however, newer strate-
gies have employed more aggressive multimodal
therapies in the neoadjuvant [7, 8] and adjuvant settings
[9–12] with some evidence of improved outcome [7, 8,
10–12].
There is lack of consensus regarding the incorporation
of peritoneal cytology into the algorithm of gastric
cancer treatment. The Japanese Gastric Cancer Associ-
ation (JGCA) includes the cytological examination of
fluid in their staging system [13]. Peritoneal cytology at
the time of diagnostic laparoscopy is recommended by
the Society of American Gastroenterologists and Endo-
scopic Surgeons (SAGES) [14], while the European
Society for Medical Oncology (ESMO) [15] considers
this step optional. The current National Comprehensive
Cancer Network (NCCN) guidelines do not explicitly
incorporate peritoneal cytology into the gastric cancer
treatment algorithm, despite later considering positive
peritoneal cytology a criterion of unresectability for cure
[16].
The methods of detecting IFCCs represent yet another
area of evolution. Traditionally, conventional cytological
evaluation of peritoneal fluid (Papanicolaou or hematoxy-
lin and eosin stains) has been employed. Low sensitivity
and a poor negative predictive value of this method have
heralded the development of advanced techniques in
detecting IFCCs—immunoassays, immunohistochemistry
(IHC), and reverse transcriptase-polymerase chain reaction
(RT-PCR). It has been suggested that these tools have
better sensitivity in detecting IFCCs with better correlation
to peritoneal recurrence [17–20].
This systematic review aims to assess the value of IF-
CCs in predicting peritoneal recurrence and overall sur-
vival in gastric cancer patients treated with curative intent,
and to determine which method, if any, is preferable for the
prediction of both peritoneal recurrence and overall sur-
vival for curative gastric cancer.
Methods
Data sources
Electronic literature searches were conducted in Medline
and EMBASE from January 1, 1998 to December 31, 2009
according to the search algorithm presented in Appendix A
in the electronic supplementary material (ESM). Search
terms included [exp Stomach Cancer/ or (((gastric or
stomach) adj1 cancer$) or ((gastric or stomach) adj1 car-
cinoma) or ((gastric or stomach) adj1 adenocarcinoma) or
((gastric or stomach) adj1 neoplasm$)).mp.] and [Lapa-
roscopy/ or peritoneal lavage/ or laparoscopic surgery/ or
Laparotomy/] or [clinical trial/ or controlled clinical trial/
or exp comparative study/ or meta analysis/ or multicenter
study/ or exp practice guideline/ or randomized controlled
trial/] not [review or case report/ or *gastrointestinal stro-
mal tumor/ or exp B cell lymphoma/ and ‘‘marginal
zone’’.mp.]. A separate search of the Cochrane Central
Register of Controlled Trials (1998–2009) was performed
using the search term ‘‘gastric cancer’’. Studies were lim-
ited to English language articles. No attempt was made to
locate unpublished material.
Study selection and review process
To be eligible, studies had to meet the following criteria:
(1) examined ascitic or lavage fluid of patients with gastric
cancer for IFCCs; (2) provided data on peritoneal recur-
rence and overall survival; (3) reported a minimum of 30
human patients with confirmed histology of gastric ade-
nocarcinoma who underwent curative resections; and (4)
were prospective studies, retrospective studies, or case
series. Studies were excluded according to the following
exclusion criteria: (1) studies where gastric adenocarci-
noma data could not be extracted from pooled results; (2)
studies using animal models; (3) studies with no patient
follow-up data; and (4) review articles, meta-analyses,
abstracts, conference proceedings, editorials/letters, and
case reports. No age, gender, or staging restrictions were
employed. All electronic search titles, selected abstracts;
and full-text articles were independently reviewed by a
minimum of two reviewers (NC, PL, and LL). Reference
lists from review papers and relevant articles were also
examined for additional studies that met our inclusion
criteria. Disagreements on study inclusion/exclusion were
resolved with a consensus meeting.
Data extraction
A systematic approach to data extraction was used to pro-
duce a descriptive summary of participants, interventions,
and study findings. The first reviewer (PL) independently
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extracted the data and a second reviewer (RC) checked the
data extraction. No attempt was made to contact authors for
additional information.
Data analysis
Many definitions were found for the calculation of accu-
racy, sensitivity, and specificity. Therefore, these values
were re-calculated from the original numbers provided in
each included publication when possible. Accuracy was
defined as follows: (number of true positives ? number of
true negatives)/(number of true positives ? false posi-
tives ? true negatives ? false negatives) 9 100. Sensi-
tivity was calculated as follows: (number of true positives)/
(number of true positives ? number of false nega-
tives) 9 100. Specificity was defined as follows: (number
of true negatives)/(number of true negatives ? number of
false positives) 9 100. Descriptive characteristics includ-
ing country of origin, study type, number of patients,
patient characteristics, disease stage, and the technique
used for peritoneal cell analysis were also collected for
each included study.
Results
Search results
A total of 1129 abstracts/citations were identified from the
electronic and hand searches for preliminary review. After
removal of duplicates and screening for relevant titles and
abstracts, a total of 435 articles were submitted for a full-
text review. Twenty-eight articles [21–48] on peritoneal
cytology for gastric cancer which satisfied the inclusion
and exclusion criteria were included in the review (Fig. 1).
The descriptive characteristics of each included study are
presented in Appendix B in the ESM.
Study and patient characteristics
Sixteen studies were prospective [24–27, 29–31, 33, 35, 37,
39, 41–45], while the remaining 12 were retrospective [21–
23, 28, 32, 34, 36, 38, 40, 46–48]. Tumor stage was
described in all but one study [35]. One article included
only locally advanced tumors [24]. The remainder included
both early and advanced cancers [21–23, 25–48].
IFCCs were identified by conventional cytology in 17
articles [21, 23, 24, 30–35, 39, 41, 42, 44–48], immuno-
assay in 6 articles [26, 33, 35, 43, 45, 46], IHC in 4
articles [22, 37, 40, 44], and RT-PCR in 14 articles [24,
25, 27–30, 35, 36, 38, 41, 42, 45–47]. Further details of
the specific analyses can be viewed in Appendix B in the
ESM.
Study findings
Study findings are summarized in Tables 1, 2, 3, 4, 5, 6,
and 7. The outcome measures of interest included the
accuracy, sensitivity, and specificity of conventional
cytology, immunoassay, IHC, and RT-PCR in predicting
peritoneal recurrence through the identification of IFCCs;
peritoneal recurrence rates in curative gastric cancer
patients with positive and negative IFCCs; and overall
survival in curative gastric cancer patients with positive
and negative IFCCS.
Prediction of peritoneal recurrence
Of the 17 articles where conventional cytology was used to
detect IFCCs, 11 commented on the risk of peritoneal
recurrence [23, 24, 30, 31, 33, 41, 42, 44–47]. Table 1
summarizes the results, with conventional cytology pre-
dicting peritoneal recurrence with an accuracy of
73–91.9%, sensitivity of 11.1–80%, and specificity of
86.4–100%.
Four of the six articles using immunoassay to detect
IFCCs commented on peritoneal recurrence [33, 43, 45,
46]. Based on these articles, the accuracy, sensitivity, and
specificity of immunoassay in predicting peritoneal recur-
rence was 72–95, 23–100, and 81–92.9%, respectively
(Table 2).
Table 3 summarizes the results of the four articles
involving IHC [22, 37, 40, 44], with a calculated accuracy,
sensitivity, and specificity of IHC in predicting peritoneal
recurrence of 54.8–76.7, 22.1–75, and 76.9–97.3%,
respectively.
Eleven studies evaluated the use of RT-PCR in pre-
dicting peritoneal recurrence [24, 25, 28–30, 38, 41, 42,
45–47]. RT-PCR predicted peritoneal recurrence with an
accuracy of 61–89.7%, sensitivity of 31–100%, and spec-
ificity of 58.8–95% (Table 4).
Articles identified from search = 1129
Articles excluded based on title and abstract = 694
Articles selected for full text review = 435
Articles excluded = 407
Articles included in this systematic review = 28
Fig. 1 Article selection flow
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Peritoneal recurrence rates by detection of IFCCs
Nineteen studies compared the peritoneal recurrence rates
in the subset of curative patients with positive versus
negative IFCCs [22–25, 28–31, 37–47]. The studies
included a variety of analysis techniques, as shown in
Table 5. Recurrence rates for patients positive for IFCCs
ranged from 11.1 to 100%, while those negative for IFCCs
Table 1 The use of IFCCs identified by conventional cytology in predicting peritoneal recurrence in curative gastric cancer patients
Study N of M0
patients
Median
follow-up
TNM
classification
Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
Euanorasetr and Lertsithichai [23] 97 1995–2005a T1-4;NX;M0 85.6c 61d 100d
Fujii et al. [24] 49 16 monthsb T3-4;NX;M0 77.6c 33.3c 97.1c
Kodera et al. 1998 [30] 123 NR T1-4;N0-3;M0 85.1c 62.5c 86.4c
Kodera et al. 1999 [31] 91 25.3 months T2-4;N0-2;M0 89c 80c 97.5c
Li et al. [33] 64 39 months T1-4;NX;M0 90.6d 73.7d 97.8d
Sugita et al. [41] 111 NR T1-4;NX;M0 87.6c 11.1c 93.3c
Tokuda et al. [42] 136 27.3 months T1-4;N0-2;M0 91.9c 31.3c 100c
Vogel et al. [44] 47 45.3 months T1-4;NX;M0 76.7c 42.9c 87c
Wang et al. [45] 40 25 months T1-4;N0-3;M0 75c 33.3c 92.9c
Yonemura et al. 2001 [46] 230 40.8 months T1-4;NX;M0 73d 46d 94d
Yonemura et al. 2001 [47] 152 28.8 months T1-4;NX;M0 79c 46c 95c
IFCCs intraperitoneal free cancer cells, N number, NR not reported/necessary information not provided
a Study period
b Minimum follow-up
c Calculated by literature review study team
d Calculations published in original manuscript
Table 2 The use of IFCCs identified by immunoassay in predicting peritoneal recurrence in curative gastric cancer patients
Study N of M0
patients
Median follow-up
(months)
TNM classification Accuracy (%) Sensitivity (%) Specificity (%) Cut-off level
Li et al. [33] 64 39 T1-4;NX;M0 85.9a,c 94.7a,c 82.2a,c 210 ng/ga
Tsutsumi et al. [43] 60 NR T0-4;NX;M0 95a,b 100a,b 92.9a,c 100 ng/ga
Wang et al. [45] 40 25 T1-4;N0-3;M0 82.5a,b 66.7a,b 89.3a,b 200 ng/ga
Yonemura et al. [46] 230 40.8 T1-4;NX;M0 72a,c 23a,c 81a,c 5 ng/mla
IFCCs intraperitoneal free cancer cells, N number, NR not reported/necessary information not provided
a Carcinoembryonic antigen (CEA)
b Calculated by literature review study team
c Calculations published in original manuscript
Table 3 The use of IFCCs identified by immunohistochemistry in predicting peritoneal recurrence in curative gastric cancer patients
Study N of M0
patients
Median follow-up
(months)
TNM classification Accuracy (%) Sensitivity (%) Specificity (%)
de Manzoni et al. [22] 168 64 T1-4;N0-3;M0 54.8a,c 22.1a,c 97.3a,c
Nekarda et al. [37] 118 64 T1-4;N0-2;M0 NR 37a,d 97a,d
Rosenberg et al. [40] 346 70 T1-4;N0-2;M0 70.2a,c 36.1a,c 85.1a,c
Vogel et al. [44] 47 45.3 T1-4;NX;M0 76.7b,c 75b,c 76.9b,c
IFCCs intraperitoneal free cancer cells, N number, NR not recorded/necessary information not provided
a Ber-EP4
b HEA-125
c Calculated by literature review study team
d Calculations published in original manuscript
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had recurrence rates of 0–51%. Minimum follow-up was
16 months, while median follow-up varied from 25 to
70 months. Statistical comparisons between recurrence
rates for patients positive and negative for IFCCs were
made in eight studies [22, 24, 31, 38, 44–47]. All eight
studies noted that patients identified as positive for IFCCs
had statistically significant higher peritoneal recurrence
rates compared to their negative counterparts.
Overall survival for curative gastric cancer patients
positive and negative for IFCCs
Tables 6 and 7 show the 2- and 5-year overall survival rates,
respectively, for curative gastric cancer patients positive and
negative for IFCCs. Twenty-four articles provided data on
2-year overall survival [21–32, 34–36, 38–40, 42–44, 46–
48], while six articles reported 5-year overall survival rates
[23, 32, 33, 37, 39, 40]. All articles found that overall survival
was significantly reduced for patients with positive IFCCs.
Discussion
The role of peritoneal lavage and ascitic fluid assess-
ment for the detection of IFCCs in gastric cancer patients
continues to evolve. Current guidelines are inconsistent in
their recommendations. SAGES recommends peritoneal
cytology at the time of diagnostic laparoscopy, but fails to
indicate the impact of the results on management deci-
sions [14]. NCCN guidelines suggest that patients with
positive peritoneal cytology be treated with palliative
therapy [16]. The Japanese currently use peritoneal
cytology for staging and prognostic purposes [13]. How-
ever, in Japan, staging laparoscopy is not a standard
practice, nor are the results always available at the time of
surgery to allow for clinical decision-making. ESMO
makes no recommendations for the use of peritoneal
cytology [15]. The numerous experimental studies con-
ducted and the vast array of analytical tools evaluated
support the belief that IFCC detection is a potentially
useful tool for clinical decision-making. However, the
management of patients with IFCCs still remains debat-
able. Challenging the traditional palliative approach to
patients with IFCCs [16], some authors suggest that the
early detection and eradication of IFCCs may improve
patient outcome [20]. The identification of IFCCs, in
medically fit patients, has the potential to impact decisions
regarding both neoadjuvant and adjuvant treatment strat-
egies, with more aggressive treatments likely being
employed in IFCC-positive patients [49].
Table 4 The use of IFCCs identified by RT-PCR in predicting peritoneal recurrence in curative gastric cancer patients
Study N of M0
patients
Median follow-up
(months)
TNM
Classification
Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
Fujii et al. [24] 49 16g T3-4;NX;M0 75.5a,h 100a,h 64.7a,h
Hara et al. [25] 126 NR T1-4;N0-2;M0 89.7c,h 80c,h 90.5c,h
Ito et al. [28] 86 38 T1-4;NX;M0 87.2a,h 84.6a,h 87.6a,h
Katsuragi et al. [29] 80 32 T1-4;N0-3;M0 NR 64.9a,i, 51.4b,i, 81.1c,i 82.3a,i, 81b,i, 79.7c,i
Kodera et al. 1998 [30] 123 NR T1-4;N0-3;M0 77.7a,h 100a,h 76.4a,h
Oyama et al. [38] 163 27 T1-4;N0-3;M0 85.3a 87.5a,h 85.2a,h
Sugita et al. [41] 111 NR T1-4;NX;M0 61c,h 88.9c,h 58.8c,h
Tokuda et al. [42] 136 27.3 T1-4;N0-2;M0 88.2a,h 93.8a,h 87.5a,h
Wang et al. [45] 40 25 T1-4;N0-3;M0 80a,h 50a,h 92.9a,h
Yonemura et al. 2001 [46] 230 40.8 T1-4;NX;M0 73a,i, 77d,i 31a,i, 57d,i 95a,i, 89d,i
Yonemura et al. 2001 [47] 152 28.8 T1-4;NX;M0 70e,h, 79f,h 33e,h, 62f,h 88e,h, 88f,h
IFCCs intraperitoneal free cancer cells, RT-PCR reverse transcriptase-polymerase chain reaction, N number, NR not reported/necessary infor-
mation not provided
a CEA
b Cytokeratin 20 (CK20)
c CEA ? CK20
d CEA ? cytology
e Matrix metalloproteinase-7 (MMP-7)
f MMP-7 ? cytology
g Minimum follow-up period
h Calculated by literature review study team
i Calculations published in original manuscript
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Methods of detection of IFCCs and their limitations
The accuracy of IFCC detection is critical for prognosti-
cation and clinical decision-making. No single test has
been found to be uniformly accurate in identifying IFCCs.
As such, testing methodology has not been standardized. In
our review, wide variations in accuracy between different
analytical methods and even between similar methods
highlight the ongoing issue. According to our review, the
sensitivities of conventional cytology, immunoassay, IHC,
and RT-PCR in predicting peritoneal recurrence vary
considerably (11.1–80, 23–100, 22.1–75, and 31–100%,
respectively). Such low sensitivities suggest that a signifi-
cant number of patients negative for IFCCs are developing
recurrence. Indeed, this is shown in Table 5, with up to
51% [22] of patients who had negative IFCC results
developing peritoneal recurrence. Even with more sensitive
detection techniques, the tests are failing to identify IFCCs,
a shortcoming that has significant management and sur-
vival implications. IFCC detection by conventional cytol-
ogy has been the gold standard to date, and this method has
been included in the JGCA [13]. Cytology has, however,
Table 5 Peritoneal recurrence rates in curative gastric cancer patients positive and negative for IFCCs
Study N of M0
patients
TNM
classification
Recurrence rates for
IFCC ? patients (%)
Recurrence rates for
IFCC - patients (%)
Median
follow-up
Statistical
significance (P)
de Manzoni et al. [22] 168 T1-4;N0-3;M0 91c,l 51c,l 64 months \0.001m
Euanorasetr and
Lertsithichai [23]
97 T1-4;NX;M0 100a,m 19a,m 1995–2005j NR
Fujii et al. [24] 49 T3-4;NX;M0 56a,m, 83.3b,m 0a,m, 23.3b,m 16 monthsk 0.00003a,m, 0.002b,m
Hara et al. [25] 126 T1-4;N0-2;M0 42.1e,l 1.9e,l NR NR
Ito et al. [28] 86 T1-4;NX;M0 55b,m 3b,m 38 months NR
Katsuragi et al. [29] 80 T1-4;N0-3;M0 65.2e,l 10e,l 32 months NR
Kodera et al. 1998 [30] 123 T1-4;N0-3;M0 20.8a,l, 19.5b,l 2.4a,l, 0b,l NR NR
Kodera et al. 1999 [31] 91 T2-4;N0-2;M0 80a,l 2.5a,l 25.3 months \0.0001m
Nekarda et al. [37] 118 T1-4;N0-2;M0 91c,l 38c,l 64 months NR
Oyama et al. [38] 163 T1-4;N0-3;M0 23.3b,l 0.8b,l 27 months SS
Ribeiro et al. [39] 220 T1-3;N0-2;M0 100a,l NR 64 months NR
Rosenberg et al. [40] 346 T1-4;N0-2;M0 51c,l 24.6c,l 70 months NR
Sugita et al. [41] 111 T1-4;NX;M0 11.1a,l, 14.5f 6.7a,l, 1.4f,l NR NR
Tokuda et al. [42] 136 T1-4;N0-2;M0 100a,l, 50b,l 8.4a,l, 0.9b,l 27.3 months NR
Tsutsumi et al. [43] 60 T0-4;NX;M0 85.7b,l 0b,l NR NR
Vogel et al. [44] 47 T1-4;NX;M0 50a,m, 66.7d,m 16.7a,m, 4.8d,m 45.3 months 0.0009a,m, 0.12d,m
Wang et al. [45] 40 T1-4;N0-3;M0 66.7a,m, 72.7b,m, 75b,m 23.5a,m, 13.8b,m, 7.4b,m 25 months \0.001m
Yonemura et al. 2001 [46] 230 T1-4;NX;M0 76h,m 21h,m 40.8 months \0.0001m
Yonemura et al. 2001 [47] 152 T1-4;NX;M0 85a,l, 57g,l, 68i,l 20a,l, 26g,l, 17i,l 28.8 months \0.001a,m, \0.01g,i,m
IFCCs intraperitoneal free cancer cells, N number, NR not reported/necessary information not provided, SS statistically significant, ? positive, -
negative
a Conventional cytology, Immunoassay
b CEA (RT-PCR)
c Ber-EP4 (immunohistochemistry)
d HEA-125 (immunohistochemistry)
e Reverse transcriptase-polymerase chain reaction
f CEA/CK20 (RT-PCR)
g MMP-7 (RT-PCR)
h Conventional cytology and CEA
i Conventional cytology and MMP-7
j Study period
k Minimum follow-up
l Calculated by literature review study team
m Calculations published in original manuscript
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been criticized for its low sensitivity and the interpretive
challenge of differentiating well-differentiated carcinoma
cells from benign mesothelial cells [17, 18]. Sensitivities
for cytology can vary greatly among institutions because of
pathologists’ experience, inter-observer variability, and the
diagnostic criteria used [30].
Table 6 2-Year overall survival for curative gastric cancer patients positive and negative for IFCCs
Study N of M0
patients
TNM
classification
Overall survival for
IFCC ? patients (%)
Overall survival for
IFCC - patients (%)
Statistical
significance (P)
Bentrem et al. [21] 371 T1-4;N0-2;M0 28a 80a \0.0001b
de Manzoni et al. [22] 168 T1-4;N0-3;M0 12a 55a \0.001b
Euanorasetr and Lertsithichai [23] 97 T1-4;NX;M0 45a 95a \0.001b
Fujii et al. [24] 49 T3-4;NX;M0 38a 90a SS
Hara et al. [25] 126 T1-4;N0-2;M0 58a 85a \0.0001b
Irinoda et al. [26] 89 T1-4;N0-3;M0 60a 100a SS
Ishii et al. [27] 51 T1-4;N0-3;M0 40a 70a 0.0069b
Ito et al. [28] 86 T1-4;NX;M0 55a 88a \0.0001b
Katsuragi et al. [29] 80 T1-4;N0-3;M0 65a 98a \0.0001b
Kodera et al. 1998 [30] 123 T1-4;N0-3;M0 28a 80a 0.014b
Kodera et al. 1999 [31] 91 T2-4;N0-2;M0 0a 88a \0.0001b
Kodera et al. 2001 [32] 34 T1-4;N0-3;M0 0a 48a 0.0380b
Miyashiro et al. [34] 417 T2-4;N1-3;M0 40a 60a \0.0001b
Mori et al. [35] 179 NR 18a 85a \0.0001b
Nakanishi et al. [36] 82 T1-4;NX;M0 37a 85a \0.01b
Oyama et al. [38] 163 T1-4;N0-3;M0 80a 98a \0.001b
Ribeiro et al. [39] 220 T1-3;N0-2;M0 0a 75a 0.00001b
Rosenberg et al. [40] 346 T1-4;N0-2;M0 75a 95a \0.001b
Tokuda et al. [42] 136 T1-4;N0-2;M0 50a 95a \0.0001b
Tsutsumi et al. [43] 60 T0-4;NX;M0 30a 95a NR
Vogel et al. [44] 47 T1-4;NX;M0 45a 82a 0.007b
Yonemura et al. 2001 [46] 230 T1-4;NX;M0 0a 60a \0.0001b
Yonemura et al. 2001 [47] 152 T1-4;NX;M0 0a 60a \0.001b; 0.002b
Yoshikawa et al. [48] 149 T1-4;N0-2;M0 30a 72a \0.0001b
IFCCs intraperitoneal free cancer cells, N number, NR not reported/necessary information not provided, SS statistically significant, ? positive, -
negative
a Estimated based on survival curves
b Calculations published in original manuscript
Table 7 5-Year overall survival for curative gastric cancer patients positive and negative for IFCCs
Study N of M0
patients
TNM
classification
Overall survival for
IFCC ? patients (%)
Overall survival for
IFCC - patients (%)
Statistical
significance
(P)
Euanorasetr and Lertsithichai [23] 97 T1-4;NX;M0 0b 75b \0.001b
Kodera et al. 2001 [32] 34 T1-4;N0-3;M0 0a 30a 0.0380b
Li et al. [33] 64 T1-4;NX;M0 15.4a 60.5a \0.05b
Nekarda et al. [37] 118 T1-4;N0-2;M0 8b 60b 0.0001b
Ribeiro et al. [39] 220 T1-3;N0-2;M0 0a 50a 0.00001b
Rosenberg et al. [40] 346 T1-4;N0-2;M0 35b 71.9b \0.001b
IFCCs intraperitoneal free cancer cells, N number, ? positive, - negative
a Estimated based on survival curves
b Calculations published in original manuscript
Peritoneal cytology in gastric cancer S33
123
IHC may be a useful ancillary test performed on con-
ventional cytological preparations. IHC techniques have
demonstrated improved detection rates of up to 14% over
conventional cytology [19]. Recently developed molecular
biologic approaches, commonly using RT-PCR, have the
potential to replace conventional morphologic techniques
due to their improved sensitivity and discriminatory value
[20]. Seven of eight studies [24, 30, 41, 42, 45–47] inclu-
ded in our review that compared RT-PCR to other methods
noted the improved sensitivity of RT-PCR over other
methods in detecting IFCCs. Despite the apparent superi-
ority of RT-PCT in detecting IFCCs, limitations do exist.
These include the illegitimate transcription of tumor-
associated genes in non-cancer cells included in the spec-
imen, the deficient expression of marker genes in IFCCs,
and the potential for limited sampling of IFCCs from the
specimen [30]. Some authors have demonstrated both low
sensitivity [47] and low specificity [24] in IFCC detection
when using carcinoembryonic antigen (CEA), the tradi-
tional target molecule for RT-PCR detection. This has
prompted the investigation of newer molecules to serve as
markers. The problem of sacrificing specificity in order to
improve sensitivity, as demonstrated by positivity in T1
cancers [28], is likely to plague other markers as well.
A separate staging procedure, with its added cost and
complication risks, is often required when assessing IFCCs
[21]. For example, the time needed for gene amplification
limits the usefulness of RT-PCR in intraoperative decision-
making [50]. Current experimental studies which aim to
identify a rapid, accurate, and cost-effective detection
method are ongoing. The transcription-reverse transcrip-
tion concerted reaction (TRC) system, as described by Ishii
et al. [27] and Ohashi et al. [51], and the LightCycler
system described by Kodera et al. [52] have shown promise
in IFCC detection by providing results in as little as 1–2 h.
Cost, however, still remains a considerable limitation.
Until an improved method of IFCC detection can be
established, the intended use of the results obtained may help
to guide the clinician in choosing an optimal detection
method. Tests with improved sensitivity often compromise
specificity, and vice versa. For example, high sensitivity is
essential in cases where aggressive therapy for IFCC-posi-
tive patients is being considered, and needs to be taken into
consideration when the method of IFCC detection is chosen.
Prognostic significance of IFCCs
The use of multiple methods of IFCC detection and the
varied accuracies of these methods can make interpretation
of the significance of results challenging. Factors contrib-
uting to this difficulty include the unknown natural history
of IFCCs and the use of varying cut-off values during
analysis. The factors responsible for IFCC proliferation and
the progression of metastatic disease, as well as the degree
and duration of dormancy of these cells, remain unknown
[20]. IFCCs may well be identified in patients who have not
been noted to develop recurrence. Here, the duration of
follow-up becomes a factor. With follow-up periods as low
as 16 months noted in our review, the recurrence rates of
IFCC-positive patients may have been underestimated. In
addition, shifting cut-off values to improve sensitivity will
ultimately reduce specificity in IFCC detection, resulting in
higher false-positive results [53].
The wide variation in peritoneal recurrence rates and
survival rates for patients positive and negative for IFCCs
demonstrates the challenge in result interpretation
(Tables 5, 6, 7). It is difficult to make recommendations for
clinical decision-making based on such varied results.
Encouraging 5-year survival rates of 35% for patients with
IFCCs, as reported by Rosenberg et al. [40], would support
a more aggressive treatment strategy. However, such rates
were not borne out by the majority of studies. Despite
variability in results, all included studies uniformly showed
that patients positive for IFCCs had a significantly higher
risk of peritoneal recurrence and lower survival rates
compared to those negative for IFCCs. The detection of
IFCCs is clearly associated with a poor prognosis. The
question remains as to the appropriate treatment strategy
for those patients with IFCCs.
Implications of IFCCs in treatment
Through the designation as Stage IV disease [6, 13] and the
well-established associated poor prognosis [4, 5], patients
with IFCCs have traditionally been offered palliative care
[7, 16]. However, some groups suggest that the prognosis
of patients with positive IFCCs can be improved through
early identification and treatment. Intraperitoneal chemo-
therapy has been demonstrated to be prophylactic against
peritoneal recurrence and to result in improved survival
[10, 54]. Both neoadjuvant and adjuvant treatment strate-
gies are currently being evaluated.
Lorenzen et al. [8] demonstrated that gastric cancer
patients whose IFCC status was converted from positive to
negative following neoadjuvant therapy had an improved
median survival (36.1 vs. 9.2 months; P = 0.002) and
longer 2-year survival (71.4 vs. 25%; P = 0.002) com-
pared to persistently IFCC-positive patients. This may be a
useful marker of biologic responsiveness to chemotherapy,
allowing surgeons to selectively offer aggressive resection
to patients in whom there is a response to induction che-
motherapy. Also, the use of extensive intraoperative peri-
toneal lavage followed by intraperitoneal chemotherapy
has been demonstrated, in a randomized controlled trial, to
improve the 5-year survival of advanced gastric cancer
patients positive for IFCCs [11].
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A recent study by Mezhir et al. [55] has proposed an
approach to these patients that appears reasonable under
these circumstances where lack of level 1 data fails to
support a specific treatment plan. Patients with M1 disease
based solely on IFCC positivity undergo chemotherapy for
6–12 months. If there has been no clinical progression,
repeat peritoneal cytology is performed. Patients who
remain positive for IFCCs are treated palliatively. Patients
who become IFCC-negative have repeat laparoscopy after
a further 3–6 months. If they revert to M1 status, they are
treated palliatively. If they remain IFCC-negative and have
good performance status, they are considered for gastrec-
tomy. Mezhir et al. [55] stress the importance of both
patient performance and re-evaluation, after an adequate
amount of time has been given for either progression of
disease or eradication, in determining the aggressiveness of
treatment. Using this strategy, they reported a resection rate
of 74% (20 of 27) for IFCC-positive patients who were
converted to negative cytology, with a 2.5-year median
disease-specific survival for those resected [55]. Given the
lack of significant prospective data for treatment outcomes
for IFCC-positive patients, it is clear that more clinical
trials are needed to determine the optimal treatment for
these patients.
Our review suffers from several limitations. Both the use
of various methods for IFCC detection and the use of
differing cut-off values make the pooling of data impos-
sible and the subsequent interpretation of results difficult.
In addition, the short median follow-up periods in the
majority of studies may falsely decrease the recurrence
rates and overestimate survival results. It was not always
possible to determine whether the patients included in
papers by a similar author were duplicated. The conclu-
sions, therefore, must be made in this context.
Conclusion
Despite the limitations of this systematic review, it appears
that the identification of IFCCs is of prognostic value,
irrespective of the detection methodology used. Their
presence is associated with a risk of peritoneal recurrence
and worse overall survival, and may be an important factor
in treatment decision-making. Although RT-PCR appears
to be a superior method of detecting IFCCs compared to
morphologically based methods, it still has limitations
related to cost, timeliness, and sampling. In order for IF-
CCs to be relevant in clinical decision-making, IFCC
detection methods need to be accurate, reliable, cost-
effective, and effective during a single procedure.
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